NICAM: Nilotinib treatment for c-KIT mutated advanced AMM

Collection of samples and data across the following diseases: Malignant melanoma of eye (disorder). Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.

Webpage:
https://www.healthdatagateway.org/dataset/c2c77d1a-d4d8-40cd-95f3-31912d4bd561

Licence:
Name: HDR UK Innovation Gateway Access
URL: https://www.hdruk.ac.uk/infrastructure/gateway/terms-and-conditions/

Tags:

malignant melanoma of eye (disorder) nicam c-kit nilotinib amm

More to explore:

1/20

Previous Next   



Need help integrating and/or managing biomedical data?